Eupraxia Pharmaceuticals (EPRX) Revenue (2023 - 2025)
Eupraxia Pharmaceuticals' (EPRX) quarterly Revenue came in at $359739.0 in Q1 2025, down 58.3% year-on-year from $862683.0 in Q1 2024, and down 58.3% on a QoQ basis from $862683.0 in Q1 2024.
Eupraxia Pharmaceuticals (EPRX) Revenue (2023 - 2025) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has 3 years of Revenue data on file, last reported at $359739.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.51 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.99 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 3.61 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.56 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Eupraxia Pharmaceuticals | 357.29 Mn | 355.69 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 359,739.00 |
| Mar 31, 2024 | 862,683.00 |
| Mar 31, 2023 | -128,152.00 |